HCPs say pharmas’ direct drug sale platforms have ‘mixed’ impact on GLP-1 access, care

5th January 2026 Uncategorised 0

A recent survey shows that healthcare professionals have varied feelings on the direct-to-patient drug sales platforms increasingly launched by pharma companies—echoing patients’ own uncertainties about the services.

More: HCPs say pharmas’ direct drug sale platforms have ‘mixed’ impact on GLP-1 access, care
Source: fierce